Omalizumab  ||| S:0 E:11 ||| NNP
for  ||| S:11 E:15 ||| IN
the  ||| S:15 E:19 ||| DT
treatment  ||| S:19 E:29 ||| NN
of  ||| S:29 E:32 ||| IN
severe  ||| S:32 E:39 ||| JJ
persistent  ||| S:39 E:50 ||| JJ
allergic  ||| S:50 E:59 ||| JJ
asthma  ||| S:59 E:66 ||| NN
in  ||| S:66 E:69 ||| IN
children  ||| S:69 E:78 ||| NNS
aged  ||| S:78 E:83 ||| VBN
6-11  ||| S:83 E:88 ||| CD
years  ||| S:88 E:94 ||| NNS
This  ||| S:94 E:99 ||| DT
paper  ||| S:99 E:105 ||| NN
presents  ||| S:105 E:114 ||| VBZ
a  ||| S:114 E:116 ||| DT
summary  ||| S:116 E:124 ||| NN
of  ||| S:124 E:127 ||| IN
the  ||| S:127 E:131 ||| DT
evidence  ||| S:131 E:140 ||| NN
review  ||| S:140 E:147 ||| NN
group  ||| S:147 E:153 ||| NN
report  ||| S:153 E:160 ||| NN
into  ||| S:160 E:165 ||| IN
the  ||| S:165 E:169 ||| DT
clinical  ||| S:169 E:178 ||| JJ
effectiveness  ||| S:178 E:192 ||| NN
and  ||| S:192 E:196 ||| CC
cost-effectiveness  ||| S:196 E:215 ||| JJ
of  ||| S:215 E:218 ||| IN
omalizumab  ||| S:218 E:229 ||| NN
for  ||| S:229 E:233 ||| IN
the  ||| S:233 E:237 ||| DT
treatment  ||| S:237 E:247 ||| NN
of  ||| S:247 E:250 ||| IN
severe  ||| S:250 E:257 ||| JJ
persistent  ||| S:257 E:268 ||| JJ
asthma  ||| S:268 E:275 ||| NN
in  ||| S:275 E:278 ||| IN
children  ||| S:278 E:287 ||| NNS
aged  ||| S:287 E:292 ||| VBN
6-11  ||| S:292 E:297 ||| CD
years ||| S:297 E:302 ||| NNS
,  ||| S:302 E:304 ||| ,
based  ||| S:304 E:310 ||| VBN
upon  ||| S:310 E:315 ||| IN
the  ||| S:315 E:319 ||| DT
evidence  ||| S:319 E:328 ||| NN
submission  ||| S:328 E:339 ||| NN
from  ||| S:339 E:344 ||| IN
Novartis  ||| S:344 E:353 ||| NNP
Pharmaceutical  ||| S:353 E:368 ||| NNP
UK  ||| S:368 E:371 ||| NNP
Ltd  ||| S:371 E:375 ||| NNP
to  ||| S:375 E:378 ||| TO
the  ||| S:378 E:382 ||| DT
National  ||| S:382 E:391 ||| NNP
Institute  ||| S:391 E:401 ||| NNP
for  ||| S:401 E:405 ||| IN
Health  ||| S:405 E:412 ||| NNP
and  ||| S:412 E:416 ||| CC
Clinical  ||| S:416 E:425 ||| NNP
Excellence  ||| S:425 E:436 ||| NNP
( ||| S:436 E:437 ||| -LRB-
NICE ||| S:437 E:441 ||| NNP
)  ||| S:441 E:443 ||| -RRB-
as  ||| S:443 E:446 ||| IN
part  ||| S:446 E:451 ||| NN
of  ||| S:451 E:454 ||| IN
the  ||| S:454 E:458 ||| DT
single  ||| S:458 E:465 ||| JJ
technology  ||| S:465 E:476 ||| NN
appraisal  ||| S:476 E:486 ||| NN
process ||| S:486 E:493 ||| NN
.  ||| S:493 E:495 ||| .
The  ||| S:495 E:499 ||| DT
manufacturer ||| S:499 E:511 ||| NN
's  ||| S:511 E:514 ||| POS
submission  ||| S:514 E:525 ||| NN
was  ||| S:525 E:529 ||| VBD
generally  ||| S:529 E:539 ||| RB
considered  ||| S:539 E:550 ||| VBN
to  ||| S:550 E:553 ||| TO
be  ||| S:553 E:556 ||| VB
of  ||| S:556 E:559 ||| IN
good  ||| S:559 E:564 ||| JJ
quality ||| S:564 E:571 ||| NN
.  ||| S:571 E:573 ||| .
The  ||| S:573 E:577 ||| DT
submission  ||| S:577 E:588 ||| NN
was  ||| S:588 E:592 ||| VBD
based  ||| S:592 E:598 ||| VBN
primarily  ||| S:598 E:608 ||| RB
on  ||| S:608 E:611 ||| IN
a  ||| S:611 E:613 ||| DT
preplanned  ||| S:613 E:624 ||| FW
subgroup  ||| S:624 E:633 ||| FW
IA-05  ||| S:633 E:639 ||| FW
EUP  ||| S:639 E:643 ||| FW
( ||| S:643 E:644 ||| -LRB-
European  ||| S:644 E:653 ||| NNP
Union  ||| S:653 E:659 ||| NNP
Population ||| S:659 E:669 ||| NNP
)  ||| S:669 E:671 ||| -RRB-
from  ||| S:671 E:676 ||| IN
the  ||| S:676 E:680 ||| DT
IA-05  ||| S:680 E:686 ||| JJ
trial ||| S:686 E:691 ||| NN
,  ||| S:691 E:693 ||| ,
with  ||| S:693 E:698 ||| IN
outcomes  ||| S:698 E:707 ||| NNS
including  ||| S:707 E:717 ||| VBG
the  ||| S:717 E:721 ||| DT
number  ||| S:721 E:728 ||| NN
of  ||| S:728 E:731 ||| IN
clinically  ||| S:731 E:742 ||| JJ
significant  ||| S:742 E:754 ||| JJ
( ||| S:754 E:755 ||| -LRB-
CS ||| S:755 E:757 ||| NNP
)  ||| S:757 E:759 ||| -RRB-
and  ||| S:759 E:763 ||| CC
clinically  ||| S:763 E:774 ||| RB
significant  ||| S:774 E:786 ||| JJ
severe  ||| S:786 E:793 ||| JJ
( ||| S:793 E:794 ||| -LRB-
CSS ||| S:794 E:797 ||| NNP
)  ||| S:797 E:799 ||| -RRB-
exacerbations ||| S:799 E:812 ||| NN
.  ||| S:812 E:814 ||| .
Omalizumab  ||| S:814 E:825 ||| JJ
therapy  ||| S:825 E:833 ||| NN
was  ||| S:833 E:837 ||| VBD
associated  ||| S:837 E:848 ||| VBN
with  ||| S:848 E:853 ||| IN
a  ||| S:853 E:855 ||| DT
statistically  ||| S:855 E:869 ||| JJ
significant  ||| S:869 E:881 ||| JJ
reduction  ||| S:881 E:891 ||| NN
in  ||| S:891 E:894 ||| IN
the  ||| S:894 E:898 ||| DT
rate  ||| S:898 E:903 ||| NN
of  ||| S:903 E:906 ||| IN
CS  ||| S:906 E:909 ||| NNP
exacerbations ||| S:909 E:922 ||| NN
,  ||| S:922 E:924 ||| ,
but  ||| S:924 E:928 ||| CC
the  ||| S:928 E:932 ||| DT
reduction  ||| S:932 E:942 ||| NN
in  ||| S:942 E:945 ||| IN
the  ||| S:945 E:949 ||| DT
rate  ||| S:949 E:954 ||| NN
of  ||| S:954 E:957 ||| IN
CSS  ||| S:957 E:961 ||| NNP
exacerbations  ||| S:961 E:975 ||| NN
was  ||| S:975 E:979 ||| VBD
not  ||| S:979 E:983 ||| RB
statistically  ||| S:983 E:997 ||| RB
significant ||| S:997 E:1008 ||| JJ
.  ||| S:1008 E:1010 ||| .
The  ||| S:1010 E:1014 ||| DT
benefit  ||| S:1014 E:1022 ||| NN
in  ||| S:1022 E:1025 ||| IN
terms  ||| S:1025 E:1031 ||| NNS
of  ||| S:1031 E:1034 ||| IN
CS  ||| S:1034 E:1037 ||| NNP
exacerbations  ||| S:1037 E:1051 ||| NN
was  ||| S:1051 E:1055 ||| VBD
achieved  ||| S:1055 E:1064 ||| VBN
mainly  ||| S:1064 E:1071 ||| RB
in  ||| S:1071 E:1074 ||| IN
patients  ||| S:1074 E:1083 ||| NNS
with  ||| S:1083 E:1088 ||| IN
more  ||| S:1088 E:1093 ||| JJR
than  ||| S:1093 E:1098 ||| IN
three  ||| S:1098 E:1104 ||| CD
exacerbations  ||| S:1104 E:1118 ||| NN
per  ||| S:1118 E:1122 ||| IN
year  ||| S:1122 E:1127 ||| NN
at  ||| S:1127 E:1130 ||| IN
baseline ||| S:1130 E:1138 ||| NN
.  ||| S:1138 E:1140 ||| .
The  ||| S:1140 E:1144 ||| DT
manufacturer  ||| S:1144 E:1157 ||| NN
found  ||| S:1157 E:1163 ||| VBD
no  ||| S:1163 E:1166 ||| DT
previous  ||| S:1166 E:1175 ||| JJ
published  ||| S:1175 E:1185 ||| VBN
cost-effectiveness  ||| S:1185 E:1204 ||| JJ
studies  ||| S:1204 E:1212 ||| NNS
of  ||| S:1212 E:1215 ||| IN
omalizumab  ||| S:1215 E:1226 ||| NN
in  ||| S:1226 E:1229 ||| IN
children  ||| S:1229 E:1238 ||| NNS
aged  ||| S:1238 E:1243 ||| VBN
6-11  ||| S:1243 E:1248 ||| CD
years ||| S:1248 E:1253 ||| NNS
,  ||| S:1253 E:1255 ||| ,
so  ||| S:1255 E:1258 ||| IN
their  ||| S:1258 E:1264 ||| PRP$
de  ||| S:1264 E:1267 ||| FW
novo  ||| S:1267 E:1272 ||| FW
economic  ||| S:1272 E:1281 ||| JJ
evaluation  ||| S:1281 E:1292 ||| NN
formed  ||| S:1292 E:1299 ||| VBD
the  ||| S:1299 E:1303 ||| DT
basis  ||| S:1303 E:1309 ||| NN
of  ||| S:1309 E:1312 ||| IN
the  ||| S:1312 E:1316 ||| DT
submitted  ||| S:1316 E:1326 ||| VBN
economic  ||| S:1326 E:1335 ||| JJ
evidence ||| S:1335 E:1343 ||| NN
.  ||| S:1343 E:1345 ||| .
The  ||| S:1345 E:1349 ||| DT
economic  ||| S:1349 E:1358 ||| JJ
model  ||| S:1358 E:1364 ||| NN
was  ||| S:1364 E:1368 ||| VBD
considered  ||| S:1368 E:1379 ||| VBN
appropriate  ||| S:1379 E:1391 ||| JJ
for  ||| S:1391 E:1395 ||| IN
the  ||| S:1395 E:1399 ||| DT
decision  ||| S:1399 E:1408 ||| NN
problem ||| S:1408 E:1415 ||| NN
.  ||| S:1415 E:1417 ||| .
The  ||| S:1417 E:1421 ||| DT
results  ||| S:1421 E:1429 ||| NNS
from  ||| S:1429 E:1434 ||| IN
the  ||| S:1434 E:1438 ||| DT
model  ||| S:1438 E:1444 ||| NN
indicated  ||| S:1444 E:1454 ||| VBD
that  ||| S:1454 E:1459 ||| DT
omalizumab  ||| S:1459 E:1470 ||| NN
in  ||| S:1470 E:1473 ||| IN
addition  ||| S:1473 E:1482 ||| NN
to  ||| S:1482 E:1485 ||| TO
standard  ||| S:1485 E:1494 ||| JJ
therapy  ||| S:1494 E:1502 ||| NN
compared  ||| S:1502 E:1511 ||| VBN
with  ||| S:1511 E:1516 ||| IN
standard  ||| S:1516 E:1525 ||| JJ
therapy  ||| S:1525 E:1533 ||| NN
alone  ||| S:1533 E:1539 ||| RB
did  ||| S:1539 E:1543 ||| VBD
not  ||| S:1543 E:1547 ||| RB
appear  ||| S:1547 E:1554 ||| VB
cost-effective  ||| S:1554 E:1569 ||| JJ
in  ||| S:1569 E:1572 ||| IN
either  ||| S:1572 E:1579 ||| RB
the  ||| S:1579 E:1583 ||| DT
overall  ||| S:1583 E:1591 ||| JJ
population  ||| S:1591 E:1602 ||| NN
or  ||| S:1602 E:1605 ||| CC
a  ||| S:1605 E:1607 ||| DT
subgroup  ||| S:1607 E:1616 ||| NN
of  ||| S:1616 E:1619 ||| IN
patients  ||| S:1619 E:1628 ||| NNS
hospitalised  ||| S:1628 E:1641 ||| VBN
in  ||| S:1641 E:1644 ||| IN
the  ||| S:1644 E:1648 ||| DT
year  ||| S:1648 E:1653 ||| NN
prior  ||| S:1653 E:1659 ||| RB
to  ||| S:1659 E:1662 ||| TO
enrollment ||| S:1662 E:1672 ||| NN
,  ||| S:1672 E:1674 ||| ,
with  ||| S:1674 E:1679 ||| IN
incremental  ||| S:1679 E:1691 ||| JJ
cost-effectiveness  ||| S:1691 E:1710 ||| JJ
ratios  ||| S:1710 E:1717 ||| NNS
of  ||| S:1717 E:1720 ||| IN
£  ||| S:1720 E:1722 ||| NNP
91,169  ||| S:1722 E:1729 ||| NNP
and  ||| S:1729 E:1733 ||| CC
£  ||| S:1733 E:1735 ||| CD
65,911  ||| S:1735 E:1742 ||| CD
per  ||| S:1742 E:1746 ||| IN
quality-adjusted  ||| S:1746 E:1763 ||| JJ
life-year ||| S:1763 E:1772 ||| NN
,  ||| S:1772 E:1774 ||| ,
respectively ||| S:1774 E:1786 ||| RB
.  ||| S:1786 E:1788 ||| .
These  ||| S:1788 E:1794 ||| DT
findings  ||| S:1794 E:1803 ||| NNS
were  ||| S:1803 E:1808 ||| VBD
found  ||| S:1808 E:1814 ||| VBN
to  ||| S:1814 E:1817 ||| TO
be  ||| S:1817 E:1820 ||| VB
robust  ||| S:1820 E:1827 ||| JJ
across  ||| S:1827 E:1834 ||| IN
a  ||| S:1834 E:1836 ||| DT
wide  ||| S:1836 E:1841 ||| JJ
range  ||| S:1841 E:1847 ||| NN
of  ||| S:1847 E:1850 ||| IN
alternative  ||| S:1850 E:1862 ||| JJ
assumptions  ||| S:1862 E:1874 ||| NNS
through  ||| S:1874 E:1882 ||| IN
one-way  ||| S:1882 E:1890 ||| JJ
sensitivity  ||| S:1890 E:1902 ||| NN
analyses ||| S:1902 E:1910 ||| NNS
.  ||| S:1910 E:1912 ||| .
The  ||| S:1912 E:1916 ||| DT
guidance  ||| S:1916 E:1925 ||| NN
issued  ||| S:1925 E:1932 ||| VBN
by  ||| S:1932 E:1935 ||| IN
NICE  ||| S:1935 E:1940 ||| NNP
states  ||| S:1940 E:1947 ||| NNS
that  ||| S:1947 E:1952 ||| IN
omalizumab  ||| S:1952 E:1963 ||| NN
is  ||| S:1963 E:1966 ||| VBZ
not  ||| S:1966 E:1970 ||| RB
recommended  ||| S:1970 E:1982 ||| VBN
for  ||| S:1982 E:1986 ||| IN
the  ||| S:1986 E:1990 ||| DT
treatment  ||| S:1990 E:2000 ||| NN
of  ||| S:2000 E:2003 ||| IN
severe  ||| S:2003 E:2010 ||| JJ
persistent  ||| S:2010 E:2021 ||| JJ
allergic  ||| S:2021 E:2030 ||| JJ
asthma  ||| S:2030 E:2037 ||| NN
in  ||| S:2037 E:2040 ||| IN
children  ||| S:2040 E:2049 ||| NNS
aged  ||| S:2049 E:2054 ||| VBN
6-11  ||| S:2054 E:2059 ||| CD
years ||| S:2059 E:2064 ||| NNS
.  ||| S:2064 E:2066 ||| .
